沙美特罗/氟替卡松复合干粉吸入剂对照布地奈德干粉吸入剂治疗哮喘的成本-效果分析

目的:评价沙美特罗/氟替卡松复合干粉吸入剂(SFC)与布地奈德干粉吸入剂(BUD)治疗哮喘的成本-效果。方法:在SFC50/100μg、bid与BUD400μg、bid治疗386例哮喘患者的多中心、随机临床对照试验基础上回顾性收集资料,进行成本-效果分析,效果指标采用成功治疗周、无症状日和未受累日;成本指标采用直接医疗服务成本。结果:SFC组的平均每日治疗成本(15.6元)略高于BUD组(13.8元),但SFC组每成功治疗周、无症状日和未受累日成本分别为166.5元、33.4元和41.2元,均低于BUD组(188.6元、50.6元和66.1元);SFC组相对于BUD组的增量成本-效果比分别为每成功治疗周88.7元、每无症状日9.4元和每未受累日10.8元。结论:SFC50/100μg、bid治疗哮喘的成本-效果优于BUD400μg、bid。

Cost- effectiveness Analysis on Salmeterol / Fluticasone Compound vs.Budesonide in the Treatment of Asthma

OBJECTIVE:To evaluate the cost-effectiveness of salmeterol/fluticasone compound(SFC)and budesonide(BUD)in the treatment of asthma.METHODS:A multicenter randomized controlled clinical trial was performed on386asthma cases,who were administered with SFC50/100μg bid or BUD400μg bid,data on which were retrospectively collected and then the cost-effectiveness analysis was conducted,the effectiveness was measured in terms of successfully-treated weeks,symptom-free days and uninvolved days;The direct healthcare cost was adopted as the cost index.RESULTS:The average daily medical cost of the SFC treatment group(RMB:15.6yuan)was a little bit higher than that of the BUD control group(RMB:13.8yuan),but the costs of every successfully-treated week,every symptom-free day and every uninvolved day for SFC group were166.5yuan,33.4yuan and41.2yuan,respectively,which were all lower than those of the BUD group(which were188.6yuan,50.6yuan and66.1yuan,respectively);Incremental cost-effectiveness ratios for every successfulˉly-treated week,per symptom-free day and per uninvolved day for the SFC group were88.7yuan,9.4yuan and10.8yuan,respectively vs.the BUD group.CONCLUSION:The results show that the cost-effectiveness of SFC50/100μg bid is supeˉrior to BUD400μg bid in the treatment of asthma.